ClinicalTrials.gg
CompletedNCT00652028Updated Apr 13, 2017Results posted

Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects

A Phase 2 interventional study of Dexmedetomidine, midazolam; fentanyl in Intubated and Mechanically Ventilated Pediatric Subjects, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 9 sites in 2 countries. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2017-04-13.

Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Non-randomized
Ages
2 Years to 16 Years
Sex
All
01

Study summary

The objective of this study is to characterize the pharmacokinetic and pharmacodynamic profile of dexmedetomidine administered as an intravenous loading dose followed by a continuous intravenous infusion in pediatric subjects ages ≥2 through \<17 years old.

Read the detailed description

This is a phase II, open-label, multicenter, escalating dose study evaluating the pharmacokinetics and pharmacodynamics of dexmedetomidine in pediatric subjects. The study population consists of initially intubated and mechanically ventilated pediatric subjects, ages ≥2 through \<17 years old, that require sedation in an intensive care setting for a minimum of 6 hours. Subjects will be divided into two groups based on age: Group I will consist of subjects ages ≥2 through \<6 years old and Group II subjects age ≥6 through \<17 years old. Within each group there will be four escalating dosing levels. Both groups can enroll simultaneously; however within each group, the next dose level cannot begin to enroll until all subjects have completed the previous dose level and the Data Safety Monitoring Board (DSMB) has approved enrollment to the next level. The level of sedation will be assessed using the Ramsay Sedation Scale (RSS). Based on these scores, and clinical judgment, additional sedation with midazolam will be administered according to the label. Pain will be assessed using the Faces, Legs, Arms, Cry \& Consolability (FLACC) scale. Venous blood samples for pharmacokinetic analysis will be obtained at designated times. The pharmacodynamic and safety measures that will be monitored and the pharmacodynamic impact of dexmedetomidine on tracheal extubation will also be explored if subject is extubated within 24 hours.

02

Conditions studied

  • Intubated and Mechanically Ventilated Pediatric Subjects

Keywords

  • Pharmacokinetics
  • Pharmacodynamics
  • Escalating dose
  • Dexmedotimidine
  • Intubated
  • Mechanically ventilated
  • Pediatrics
03

In context

Lead sponsor

Hospira, now a wholly owned subsidiary of Pfizer is the lead sponsor of 28 studies on the registry; none are open to participants now.

First submitted before Hospira became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Initially intubated and mechanically ventilated pediatric subjects in an intensive care setting anticipated to require a minimum of 6 hours of continuous intravenous sedation.
  • Age: subjects must fit into one of the following age ranges at screening:

    • ≥2 years old through \<6 years old
    • ≥6 years old through \<17 years old
  • If female, subject is non-lactating and is either:

    1. Not of , defined as pre-menarche, or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy or hysterectomy.
    2. Of childbearing potential but is not pregnant at time of baseline.
  • Subject's parent(s) or legal guardian(s) has/have voluntarily signed and dated the document approved by the Institutional Review Board. Assent will be obtained where age-appropriate and according to state regulations.

Exclusion criteria

Exclusion Criteria:

  • Pediatric subjects with neurological conditions that prohibit an evaluation of sedation

    • Diminished consciousness from increased intracranial pressure.
    • Extensive brain surgery (surgery requiring intracranial pressure monitor).
    • Diminished cognitive function per PI's discretion.
    • Subjects with immobility from neuromuscular disease or continuous infusion of neuromuscular blocking agents.
  • Weight \<10 kg.
  • Subjects with second degree or third degree heart block unless subject has a pacemaker or pacing wires.
  • Hepatic impairment Serum glutamic pyruvic transaminase/ (SGPT/ALT) >100 U/L
  • Hypotension based on repeat assessments prior to starting study drug:

    • Age ≥2 years old through ≤12 years old: systolic blood pressure (SBP) \<80 mmHg
    • Age >12 years old through \<17 years old: SBP \<90 mmHg
  • Pre-existing bradycardia prior to starting study drug defined as:

    • Age ≥2 years old through ≤6 years old: ≤70 beats per minute (bpm)
    • Age >6 years old through ≤12 years old: ≤60 bpm
    • Age >12 years old through ≤16 years old: ≤50 bpm
  • Acute thermal burns involving more than 15 percent total body surface area.
  • Subjects who have a known allergy to dexmedetomidine, midazolam (MDZ) or fentanyl.
  • Subjects with a that is \<72 hours.
  • Subjects that are expected to have hemodialysis (continuous hemofiltration) or peritoneal dialysis within 48 hours.
  • Subjects who have been treated with α-2 agonists/antagonists within two weeks.
  • Subjects with a spinal cord injury above T5.
  • Subjects who have received another drug within the past 30 days.
  • Subjects on nicotine replacement therapy.
  • Subjects who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of this clinical study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Other
    Group 1

    Dose level 1

    Drug: Dexmedetomidine, midazolam; fentanyl

  • Other
    Group 2

    Dose level 2

    Drug: Dexmedetomidine, midazolam; fentanyl

  • Other
    Group 3

    Dose level 3

    Drug: Dexmedetomidine, midazolam; fentanyl

  • Other
    Group 4

    Dose level 4

    Drug: Dexmedetomidine, midazolam; fentanyl

Interventions

  • DrugDexmedetomidine, midazolam; fentanyl

    Drug pages: Dexmedetomidine · Midazolam · Fentanyl

    Dexmedetomidine for sedation; midazolam for rescue sedation according to label; fentanyl for rescue pain according to the label

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t)

    Area under the concentration-time curve from time zero to the time of the last measurable concentration (AUC0-t) for Dexmedetomidine

    Time frame: ≤30 min prior to start of loading dose (LD); 5 min before finishing LD; 0.5,1,2 & 4-6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (within 24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4 & 10 hrs after end of MI.

  2. Area Under the Concentration-time Curve From Time Zero to the Time Infinity (AUC0-∞)

    Area under the concentration-time curve from time zero to the time infinity (AUC0-∞) for Dexmedetomidine

    Time frame: ≤30 min prior to start of the loading dose (LD); 5 min before finishing the LD; 0.5,1,2&4 to 6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4&10 hrs after end of MI.

  3. Observed Peak Plasma Concentration

    Observed peak plasma concentration (Cmax) for Dexmedetomidine

    Time frame: ≤30 min prior to start of the loading dose (LD); 5 min before finishing the LD; 0.5,1,2&4 to 6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4&10 hrs after end of MI.

  4. Terminal Elimination Half-life (t1/2)

    Terminal elimination half-life (t1/2) for Dexmedetomidine

    Time frame: ≤30 min prior to start of loading dose (LD); 5 min before finishing LD; 0.5,1,2 & 4-6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (within 24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4 & 10 hrs after end of MI.

  5. Plasma Concentration at Steady State (Css)

    Plasma concentration at steady state (Css) for Dexmedetomidine

    Time frame: ≤30 min prior to start of loading dose (LD); 5 min before finishing LD; 0.5,1,2 & 4-6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (within 24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4 & 10 hrs after end of MI.

  6. Volume of Steady State Distribution (Vss)

    Volume of steady state distribution (Vss) for Dexmedetomidine

    Time frame: ≤30 min prior to start of loading dose (LD); 5 min before finishing LD; 0.5,1,2 & 4-6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (within 24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4 & 10 hrs after end of MI.

  7. Clearance (CL)

    Clearance (CL) for Dexmedetomidine

    Time frame: ≤30 min prior to start of loading dose (LD); 5 min before finishing LD; 0.5,1,2 & 4-6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (within 24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4 & 10 hrs after end of MI.

  8. Level of Sedation Based on Average Ramsay Sedation Scale (RSS) Score

    RSS Score range from 1 to 6: 1. Patient is anxious and agitated or restless, or both. 2. Patient is cooperative, orientated and tranquil. 3. Patient responds to command only. 4. Patient exhibits brisk response to light glabellar (between the eyebrows) tap or loud auditory stimulus. 5. Patient exhibits a sluggish response to light glabellar tap or loud auditory stimulus. 6. Patient exhibits no response to stimulus.

    Time frame: Prior to loading (Baseline), 5 and 10 min during the load, at start of maintenance infusion and every 15 min for 1 hour, hourly during the maintenance period, before and within 5 min after midazolam or fentanyl dose during the dexmedetomidine infusion.

  9. Number of Subjects Who Received Rescue Medication for Sedation (Midazolam) and Analgesics (Fentanyl)

    Number of subjects who received rescue medication for Sedation (Midazolam) and analgesics (Fentanyl) while intubated during Treatment Period

    Time frame: During the treatment period (Approximately 24 hours)

07

Results

Posted Aug 14, 2015

Participant flow

Participant flow — Overall Study
MilestoneDose Level 1Dose Level 2Dose Level 3Dose Level 4
Started16141514
Completed15131414
Not completed1110
Withdrew: Adverse event1000
Withdrew: No longer meets entry criteria0100
Withdrew: Physician decision0010

Outcome measures

PrimaryArea Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t)

Area under the concentration-time curve from time zero to the time of the last measurable concentration (AUC0-t) for Dexmedetomidine

Time frame:
≤30 min prior to start of loading dose (LD); 5 min before finishing LD; 0.5,1,2 & 4-6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (within 24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4 & 10 hrs after end of MI.
Reported as:
Mean · picograms*hr/mL
Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t)
picograms*hr/mLDose Level 1Dose Level 2Dose Level 3Dose Level 4
Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t)2681.332 ± 2353.34186460.576 ± 3766.465716992.540 ± 29927.391128531.864 ± 17496.3985
PrimaryArea Under the Concentration-time Curve From Time Zero to the Time Infinity (AUC0-∞)

Area under the concentration-time curve from time zero to the time infinity (AUC0-∞) for Dexmedetomidine

Time frame:
≤30 min prior to start of the loading dose (LD); 5 min before finishing the LD; 0.5,1,2&4 to 6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4&10 hrs after end of MI.
Reported as:
Mean · picograms*hr/mL
Area Under the Concentration-time Curve From Time Zero to the Time Infinity (AUC0-∞)
picograms*hr/mLDose Level 1Dose Level 2Dose Level 3Dose Level 4
Area Under the Concentration-time Curve From Time Zero to the Time Infinity (AUC0-∞)3153.518 ± 3343.34516673.163 ± 3781.218317300.539 ± 29935.764728970.541 ± 17936.8970
PrimaryObserved Peak Plasma Concentration

Observed peak plasma concentration (Cmax) for Dexmedetomidine

Time frame:
≤30 min prior to start of the loading dose (LD); 5 min before finishing the LD; 0.5,1,2&4 to 6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4&10 hrs after end of MI.
Reported as:
Mean · picograms per milliliter
Observed Peak Plasma Concentration
picograms per milliliterDose Level 1Dose Level 2Dose Level 3Dose Level 4
Observed Peak Plasma Concentration480.437 ± 625.9946847.691 ± 633.73523385.569 ± 7384.06993090.939 ± 1625.5241
PrimaryTerminal Elimination Half-life (t1/2)

Terminal elimination half-life (t1/2) for Dexmedetomidine

Time frame:
≤30 min prior to start of loading dose (LD); 5 min before finishing LD; 0.5,1,2 & 4-6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (within 24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4 & 10 hrs after end of MI.
Reported as:
Mean · hour
Terminal Elimination Half-life (t1/2)
hourDose Level 1Dose Level 2Dose Level 3Dose Level 4
Terminal Elimination Half-life (t1/2)1.546 ± 0.34011.743 ± 0.30182.045 ± 0.65822.145 ± 0.6763
PrimaryPlasma Concentration at Steady State (Css)

Plasma concentration at steady state (Css) for Dexmedetomidine

Time frame:
≤30 min prior to start of loading dose (LD); 5 min before finishing LD; 0.5,1,2 & 4-6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (within 24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4 & 10 hrs after end of MI.
Reported as:
Mean · picograms per milliliter
Plasma Concentration at Steady State (Css)
picograms per milliliterDose Level 1Dose Level 2Dose Level 3Dose Level 4
Plasma Concentration at Steady State (Css)402.026 ± 535.1718539.848 ± 166.74231347.284 ± 1308.09882827.144 ± 1169.4226
PrimaryVolume of Steady State Distribution (Vss)

Volume of steady state distribution (Vss) for Dexmedetomidine

Time frame:
≤30 min prior to start of loading dose (LD); 5 min before finishing LD; 0.5,1,2 & 4-6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (within 24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4 & 10 hrs after end of MI.
Reported as:
Mean · Litre
Volume of Steady State Distribution (Vss)
LitreDose Level 1Dose Level 2Dose Level 3Dose Level 4
Volume of Steady State Distribution (Vss)56.808 ± 44.512735.246 ± 25.023332.789 ± 22.547843.652 ± 30.6577
PrimaryClearance (CL)

Clearance (CL) for Dexmedetomidine

Time frame:
≤30 min prior to start of loading dose (LD); 5 min before finishing LD; 0.5,1,2 & 4-6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (within 24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4 & 10 hrs after end of MI.
Reported as:
Mean · Litre/hour
Clearance (CL)
Litre/hourDose Level 1Dose Level 2Dose Level 3Dose Level 4
Clearance (CL)32.208 ± 40.398220.268 ± 10.350818.565 ± 8.699522.199 ± 14.1623
PrimaryLevel of Sedation Based on Average Ramsay Sedation Scale (RSS) Score

RSS Score range from 1 to 6: 1. Patient is anxious and agitated or restless, or both. 2. Patient is cooperative, orientated and tranquil. 3. Patient responds to command only. 4. Patient exhibits brisk response to light glabellar (between the eyebrows) tap or loud auditory stimulus. 5. Patient exhibits a sluggish response to light glabellar tap or loud auditory stimulus. 6. Patient exhibits no response to stimulus.

Time frame:
Prior to loading (Baseline), 5 and 10 min during the load, at start of maintenance infusion and every 15 min for 1 hour, hourly during the maintenance period, before and within 5 min after midazolam or fentanyl dose during the dexmedetomidine infusion.
Reported as:
Mean · units on a scale
Level of Sedation Based on Average Ramsay Sedation Scale (RSS) Score
units on a scaleDose Level 1Dose Level 2Dose Level 3Dose Level 4
Level of Sedation Based on Average Ramsay Sedation Scale (RSS) Score2.4 ± 0.962.8 ± 0.742.4 ± 0.54.0 ± 1.04
PrimaryNumber of Subjects Who Received Rescue Medication for Sedation (Midazolam) and Analgesics (Fentanyl)

Number of subjects who received rescue medication for Sedation (Midazolam) and analgesics (Fentanyl) while intubated during Treatment Period

Time frame:
During the treatment period (Approximately 24 hours)
Reported as:
Number · participants
Number of Subjects Who Received Rescue Medication for Sedation (Midazolam) and Analgesics (Fentanyl)
participantsDose Level 1Dose Level 2Dose Level 3Dose Level 4
Midazolam7753
Fentanyl1210138

Adverse events

Collected over From the start of study drug administration until 24 hours following discontinuation of study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level 1—1/16 (6.3%)11/16 (68.8%)
Dose Level 2—0/14 (0%)12/14 (85.7%)
Dose Level 3—0/15 (0%)10/15 (66.7%)
Dose Level 4—0/14 (0%)13/14 (92.9%)
Most frequent serious events
Most frequent serious events
EventDose Level 1Dose Level 2Dose Level 3Dose Level 4
ConvulsionNervous system disorders1/160/140/150/14
Most frequent other events
Showing 10 of 52
Most frequent other events
EventDose Level 1Dose Level 2Dose Level 3Dose Level 4
VomitingGastrointestinal disorders1/164/142/152/14
PyrexiaGeneral disorders4/164/142/153/14
HypokalaemiaMetabolism and nutrition disorders4/163/141/153/14
SedationNervous system disorders0/160/140/153/14
HypertensionVascular disorders2/162/143/153/14
NauseaGastrointestinal disorders1/162/141/152/14
PainGeneral disorders0/161/140/152/14
Procedural painInjury, poisoning and procedural complications1/162/140/150/14
HyperglycaemiaMetabolism and nutrition disorders1/160/140/152/14
Pleural effusionRespiratory, thoracic and mediastinal disorders1/160/140/152/14

Baseline characteristics

Safety Population: Participants who received any amount of study drug were included in the Safety Population

Age, Continuous
Age, Continuous(years)Dose Level 1Dose Level 2Dose Level 3Dose Level 4Total
Mean6.358 ± 3.46737.457 ± 4.59908.379 ± 4.49627.462 ± 4.22597.395 ± 4.1571
Age, Customized
Age, Customized(participants)Dose Level 1Dose Level 2Dose Level 3Dose Level 4Total
≥2 through <6 years866626
≥6 through <17 years889833
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level 1Dose Level 2Dose Level 3Dose Level 4Total
Female1089532
Male666927
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Level 1Dose Level 2Dose Level 3Dose Level 4Total
American Indian or Alaska Native10001
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American12126
White1212131047
More than one race20002
Unknown or Not Reported00123
08

Study locations

9 sites
  • Miami Children's Hospital
    Miami, Florida 33155, United States
  • University of Louisville/Kosair Children's Hospital
    Louisville, Kentucky 40202, United States
  • Women and Children's Hospital of Buffalo
    Buffalo, New York 14222, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University Hospitals Medical Center
    Cleveland, Ohio 44106, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23219, United States
  • Unidad Cirugia Cardiovascular de Guatemala
    Guatemala City, Guatemala
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 5 years 4 months after primary completion. A results delay was requested in Sep 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2008
First posted
Apr 3, 2008
Start
Nov 2008
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Results delay requested
Sep 6, 2011
Results first posted
Aug 14, 2015
Last update
Apr 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00652028
Responsible party
Sponsor
First posted
Apr 3, 2008
Start date
Nov 2008
Primary completion
Apr 2010
Completion
Apr 2010
Results posted
Aug 14, 2015
Last update
Apr 13, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Midazolam · Fentanyl

Start the discussion